User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Jun 23 2016 12:45 IST RSS 2.0
 
1 to 20 of 2,738    
Delhi High Court asks Roche to explain lawsuit over Avastin copy 24.5.2016 ET: Pharma
Roche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to bevacizumab.
Also found in: [+]
Pharma exports growth heading for a sharp decline, Crisil says 17.5.2016 TOI: India Business
ith the value of drugs going off-patent declining amid an increase in pricing pressures, exports growth in pharmaceutical formulations (in US dollar terms) would decline sharply to 10%-12% annually over the next five years, compared with a growth of about 19% achieved in the last decade, ratings agency Crisil has said.
Also found in: [+]
#dnaEdit: India must resist pressure to amend its patent laws 17.5.2016 DNA: Top News
The National Intellectual Property Rights (IPR) Policy promises to overhaul patents administration in India, but has raised concerns in the pharmaceutical industry and among those who seek a balance between IPR and free access to knowledge. Finance minister Arun Jaitley has asserted that India would retain its right to compulsory licensing in public interest to meet contingencies, and there would be no changes to Section 3(d) of the Indian Patents Act, which prevents ever-greening of drug patents. Though the policy claims that India’s patent laws are compliant with the Doha Declaration and the TRIPS (Trade Related Aspects of Intellectual Property Rights) Agreement, certain provisions in the policy document have alarmed the generic drugs industry. It promises to “carry out legislative changes” whenever existing laws become inadequate to address changes in the knowledge field.  With India constantly pressured by developed countries to amend its patent laws, it is feared that these changes can proceed only ...
Also found in: [+]
Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rights 16.5.2016 ET: Pharma
Legal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata Patent Office.
Also found in: [+]
IPR policy lacks specifics, won't be enough to foster innovation: Lobby groups 16.5.2016 ET: Policy
Some experts said the policy is an attempt to calm the nerves of India’s trade partners – especially the US – but has left stakeholders wanting more.
Also found in: [+]
India unveils intellectual property rights policy 14.5.2016 Sify Finance
The Indian cabinet has given its approval to the country's first Intellectual Rights Property (IRP) policy in a bid to give an impetus to ease of doing business in the country.
Also found in: [+]
IPR policy to ensure patents don’t hit affordability of life-saving drugs: FM Arun Jaitley 14.5.2016 ET: Policy
Finance minister Arun Jaitley, who unveiled the policy after getting clearance from the Union cabinet, said the process to register a trademark may take only a month from next year.
Also found in: [+]
By 2017, it will only take one month to register trademarks, FM Jaitley promises 14.5.2016 DNA: Mumbai
Finance Minister Arun Jaitley on Friday said the government is putting in place a mechanism to drastically bring down the time period for registration of a trademark to one month by 2017. He said: "Now in India, we have a very effective and a robust trademark law in place... It takes a lot of time for getting the registration done and our plan is to facilitate online applications and bring down the time period to one month by 2017." The move would help in cutting down the pendency of applications. The total number of patent applications and trademark registration requests pending as on February 1, 2016, are 2,37,029 and 5,44,171 respectively. Talking about the national IPR policy, the minister said capacity would be built to achieve objectives of the policy. Further, he said one has to balance the consideration of inventibility with public health considerations so that cost of medicines does not become prohibited because patent may itself create a monopoly. On compulsory licensing (CL), he said so far, ...
Also found in: [+]
Government announces IPR policy, lines up incentives for R&D 14.5.2016 DNA: Wide Angle
The government has announced a comprehensive National Intellectual Property Rights (IPR) policy, in a move to incentivise entrepreneurship, creativity and innovation and curb manufacturing and sale of counterfeits. The policy, with a tagline of 'Creative India: Innovative India', also calls for updating various intellectual property laws, including the Indian Cinematography Act, to remove anomalies and inconsistencies in consultation with stakeholders. "The aim is to create awareness about economic, social and cultural benefits of IPRs among all sections of society... The policy aims to create and exploit synergies between all forms of IP, statutes concerned and agencies," Finance Minister Arun Jaitley said while briefing reporters about the yesterday's Cabinet decision. On trademark, Jaitley said the registration process will be reduced to one month by 2017. The seven objectives of the policy, he said, include IPR awareness, stimulation of generation of IPRs, need for strong and effective laws and ...
Also found in: [+]
IPR policy to ensure patents don’t hit affordability of life-saving drugs: FM 14.5.2016 TOI: India Business
Also found in: [+]
Government approves new IPR policy; India Inc hails move while pharma firms wary about changes 14.5.2016 ET: Policy
The government has approved a new IPR policy that seeks to encourage innovation and improve access to healthcare, food security and environmental protection.
Also found in: [+]
India to drastically reduce trademark registration time: FM 13.5.2016 TOI: India Business
"Now in India, we have a very effective and a robust trademark law in place...
Also found in: [+]
Gilead patent on sofosbuvir a setback for health groups, but they vow to fight on 12.5.2016 TOI: India Business
A day after US company Gilead was granted a patent on hepatitis C medicine, sofosbuvir, patient groups and companies are planning to challenge it.
Also found in: [+]
Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc 11.5.2016 ET: Pharma
"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson added.
Also found in: [+]
Morning News Call - India, May 11 11.5.2016 Sify Finance
To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_05112016.pdf
Also found in: [+]
India Patent Office approves Gilead's hepatitis C drug patent 11.5.2016 Sify Finance
By Deena Beasley
Also found in: [+]
Gilead’s $1,000 pill gets patent in India 10.5.2016 ET: Pharma
Gilead's patent application was first rejected - just before President Obama's visit in 2015 January - which was seen to be upsetting the US government.
Also found in: [+]
Gilead’s $1,000 pill gets patent in India 10.5.2016 TOI: India Business
In what could be a major setback to access to treatment in high-burden countries, the Indian Patent Office on Monday granted a patent to Gilead Pharmasset on Sovaldi (sofosbuvir), its blockbuster drug for hepatitis C, for which the company charges $1,000 per pill in the US.
Also found in: [+]
US watch list may hit affordable drug business 3.5.2016 ET: Pharma
India remains on Priority Watch List, and continues to be singled out for what the USTR considers to be inadequate protection of intellectual property.
Also found in: [+]
FDI during April-February jumps to $37.53 billion, government says 2.5.2016 TOI: India Business
Foreign direct investment in India increased to $37.53 billion during April-February period of the last fiscal,​ commerce and industry minister Nirmala Sitharaman said in a written reply to the Lok Sabha​ on Monday. It was $30.93 billion in 2014-15.
Also found in: [+]
1 to 20 of 2,738